Immunovant/IMVT

$30.47

3.81%
-
1D1W1MYTD1YMAX

About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.

Ticker

IMVT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Peter Salzmann

Employees

164

Headquarters

New york, United States

Immunovant Metrics

BasicAdvanced
$4.26B
Market cap
-
P/E ratio
-$1.83
EPS
0.72
Beta
-
Dividend rate
$4.26B
0.72225
$45.58
$14.11
1.13M
22.141
-41.7%
-44.51%
-44.49%
6.269
6.277
-10.34%

What the Analysts think about Immunovant

Analyst Ratings

Majority rating from 17 analysts.
Buy

Price Targets

Average projection from 15 analysts.
66.29% upside
High $57.00
Low $40.00
$30.47
Current price
$50.67
Average price target

Immunovant Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
-
Net income
$-51.4M
-12.29%
Profit margin
0%
-

Immunovant Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.53%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
-$0.46
-$0.57
-$0.45
-$0.36
-
Expected
-$0.43
-$0.45
-$0.47
-$0.43
-$0.43
Surprise
7.52%
27.71%
-4.37%
-16.53%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Immunovant stock?

Immunovant (IMVT) has a market cap of $4.26B as of April 16, 2024.

What is the P/E ratio for Immunovant stock?

The price to earnings (P/E) ratio for Immunovant (IMVT) stock is 0 as of April 16, 2024.

Does Immunovant stock pay dividends?

No, Immunovant (IMVT) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Immunovant dividend payment date?

Immunovant (IMVT) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunovant?

Immunovant (IMVT) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Immunovant stock price target?

The target price for Immunovant (IMVT) stock is $50.67, which is 66.29% above the current price of $30.47. This is an average based on projections from 15 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Immunovant stock

Buy or sell Immunovant stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing